Halozyme Therapeutics Inc. and Merus N.V. have entered into a global non-exclusive collaboration and license agreement. Under the terms of the agreement, Merus will make an upfront payment to Halozyme, with potential future milestone payments related to commercial and sales attainment if approved. Halozyme will also be entitled to receive up to low-mid single digit royalties on net sales of petosemtamab formulated with the ENHANZE® technology during the royalty term. The collaboration grants Merus a license to use Halozyme's ENHANZE® drug delivery technology for the development and potential commercialization of a subcutaneous formulation of petosemtamab, an EGFR x LGR5 bispecific antibody.